期刊文献+

他汀类药物在急性冠脉综合征中的应用进展 被引量:10

Application progress of Statins in acute coronary syndromes
下载PDF
导出
摘要 他汀类药物具有肯定的降脂作用,已作为冠状动脉粥样硬化性心脏病的二级预防用药。大量研究显示,他汀类药物还具有除降脂之外的抑制炎症反应、抗心室重塑、改善神经体液调节、抗心律失常、改善血管内皮功能、抗氧化等作用。本文对他汀类药物治疗急性冠脉综合征的临床依据和可能的机制作一综述。 Statins plays a role in reducing blood LDL cholesterol, acting as a second-level prevention drug for coronary artery disease. Many studies have shown that Statins have many other contributions to anti-inflammation, anti-ventricular remodeling, anti-arrhythmia, anti-oxidation and improvement of neurohumoral regulation and endothelial function besides their effect on blood fat decrease. This paper aims to investigate the clinical basis and possible mechanisms for Statins in the treatment of acute coronary syndromes.
作者 刘明伟 曲艳
出处 《中国医药导报》 CAS 2009年第29期5-6,共2页 China Medical Herald
关键词 他汀类药物 急性冠脉综合征 治疗 Statins Acute coronary syndromes Therapy
  • 相关文献

参考文献1

二级参考文献35

  • 1Ichihara S, Noda A, Nagata K, Obata K, Xu J, Ichihara G, et al. Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure. Cardiovasc Res 2006; 69: 726-35.
  • 2Chen MS, Xu FP, Wang YZ, Zhang JE Yi Q, Zhang HQ et al. Statins initiated after hypertrophy inhibit oxidative stress and prevent heart failure in rats with aortic stenosis. J Mol Cell Cardiol 2004; 37: 889-96.
  • 3Hatt PY, Rakusan K, Gastineau P, Laplace M. Morphometry and ultrastructure of heart hypertrophy induced by chronic volume overload (aorto-caval fistula in the rat). J Mol Cell Cardiol 1979; 11: 989-98.
  • 4Pieruzzi F, Abassi ZA, Keiser HR. Expression of renin-angiotensin system components in the heart, kidneys and lungs of rats with experimental heart failure. Circulation 1995; 92: 3105-12.
  • 5Wang X, Ren B, Lui S, Sentex E, Tappia PS, Dhalla NS. Characterization of cardiac hypertrophy and heart failure due to volume overload in the rat. J Appl Physiol 2003; 94: 752-63.
  • 6Pourati I, Kimmelstiel C, Rand W, Karas RH. Statin use is associated with enhanced collateralization of severely diseased coronary arteries. Am Heart J 2003; 146: 876-81.
  • 7Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 2004; 109: 2850-6.
  • 8Banff C, Cavalca V, Veglia F, Brioschi M, Barcella S, Mussoni L, et al. Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure. Eur Heart J 2005; 26: 481-8.
  • 9Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002, 105: 868-73.
  • 10Boixel C, Fontaine V, Rucker-Martin C, Milliez P, Louedec L, Michel JB, et al. Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. J Am Coll Cardiol 2003; 42: 336-44.

共引文献6

同被引文献100

引证文献10

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部